Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24
H1 2023/24 Interim financial results, H1 2023/241 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin 1)of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.Organic growth rates by business area: Ostomy Care 7%, Continence Care 8%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 8%) and Interventional...
Nasdaq GlobeNewswire
07/05/2024
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate…
Valneva Reports First Quarter 2024 Financial Results andProvides Corporate UpdatesQ1 financial highlightsTotal revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidanceCash position of €176.6 million, including €95 million from sale of Priority Review Voucher (PRV) 1.Significantly extended cash runway with recent update of debt financing agreement 2 Substantially lower cash burn expected in 2024 as Valneva expects to...
Nasdaq GlobeNewswire
07/05/2024
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General…
Ultimovacs remains committed to continuing the clinical development strategy and exploring multiple pathways for UV1. The negative INITIUM results have had important consequences for the Company. Implemented cash preservation initiatives extends the anticipated financial runway to the fourth quarter of 2025, beyond the anticipated topline readout of the FOCUS and DOVACC trials. The UV1 vaccine was granted Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan...
Nasdaq GlobeNewswire
07/05/2024
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong first quarter performance, with net sales[1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024Basel, May 7, 2024 –Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced...
Nasdaq GlobeNewswire
07/05/2024
AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange
Denis Machuel, Adecco Group CEO, commented: Denis Machuel, Adecco Group CEO, commented: "The Group demonstrated strong operational progress in the first quarter. We achieved revenue stability and maintained firm pricing discipline amidst challenging market conditions while driving further cost improvement across the business. Adecco delivered significant market share gains with a healthy gross margin. Akkodis faced ongoing tech staffing headwinds while achieving solid growth in its...
PR Newswire
07/05/2024
The 26th China (Guangzhou) International Building Decoration Fair Scheduled for…
The 2024 CBD (Guangzhou) is set to further its legacy with an expanded exhibition space of 420,000 square meters and an estimated 2,200 participating companies. The event will feature an optimized and upgraded "5+1" layout, encompassing five thematic areas and the second Guangzhou International Sanitary and Bath Ware Fair, which is set to take place concurrently with the 2024 CBD (Guangzhou) in Area A of the Canton Fair Complex. The approach highlights the CBD (Guangzhou)'s…
PR Newswire
07/05/2024
Biogénesis Bagó and ACSAD working together to improve livestock productivity in…
The agreement was signed by Dr. Nasr Al-Din Obaid, Director General of ACSAD and the CEO of Biogenesis Bagé, Mr. Esteban Turic. During the event the Ministers of Agriculture of Jordan, Mr. Khaled Hanifat, and Lebanon, Mr. Abbas Al-Haj Hassan, as well as Daniel Helou, Biogénesis Bagó's Regional Director for MENA and Central Asia were also present. This agreement is key in promoting joint efforts that allow the region's authorities to make available scientific and quality solutions to improve the…
PR Newswire
06/05/2024
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)PARIS, May06, 2024(GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 04/30/202471,955,53577,891,229 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,
[email protected]
Patricia...
Nasdaq GlobeNewswire
06/05/2024
Trading in Novo Nordisk shares by board members, executives and associated…
Bagsværd, Denmark, 06 May 2024– This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
06/05/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 May 2024– The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the...
Nasdaq GlobeNewswire
06/05/2024
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings…
Bagsværd, Denmark, 06 May 2024– Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market...
Nasdaq GlobeNewswire
06/05/2024
Bondholders approve amended terms of the 2024 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the bondholders and will become binding and effective upon approval by the higher cantonal composition authority.Allschwil, Switzerland – May 6, 2024Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of a bondholder meeting held at 17:30 CEST on May 6, 2024. The bondholder meeting...
Nasdaq GlobeNewswire
06/05/2024
FDI Summit Costa Rica: First edition of the event attracts new investors to the…
The FDI Summit is focused on the country's strategic sectors such as agribusiness, light and advanced manufacturing, life sciences, corporate services, digital technologies, semiconductors and tourism infrastructure. This diversification of sectors seeks to guarantee investment opportunities in all regions of the country. The FDI Summit is focused on the country's strategic sectors such as agribusiness, light and advanced manufacturing, life sciences, corporate services, digital technologies,...
PR Newswire
06/05/2024
Ipsen - Monthly information relative to the total number of voting rights and…
Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)30 April 202483,814,526Gross...
Nasdaq GlobeNewswire
06/05/2024
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to…
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMDLeuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD).This recently launched program has reached the first step with the identification of 50...
Nasdaq GlobeNewswire
06/05/2024
Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
Press ReleaseNicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings May 6, 2024 – release at 17h45 CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, announced that the Ordinary and Extraordinary General Meetings were held today, on second convening...
Nasdaq GlobeNewswire
06/05/2024
Injectable Drug Delivery Market Worth $1139.4 billion | MarketsandMarkets™
Emerging economies are seeing rapid urbanization, improved healthcare infrastructure, and more healthcare spending, resulting in greater access to injectable drugs. As a result, pharmaceutical companies are focusing on extending their presence in these markets to drive market growth. Emerging economies are seeing rapid urbanization, improved healthcare infrastructure, and more healthcare spending, resulting in greater access to injectable drugs. As a result, pharmaceutical companies are...
PR Newswire
06/05/2024
Remote Patient Monitoring Market to Be Worth $116.84 Billion by 2031 - Exclusive…
Remote patient monitoring involves the use of connected medical devices to measure and monitor patient health data and transmit it to the healthcare provider. It also involves the use of software platforms to transmit the data to healthcare providers, where they can analyze the information and generate actionable insights. Healthcare professionals can intervene in disease management as necessary, either in person or virtually. Remote patient monitoring involves the use of connected medical...
PR Newswire
06/05/2024
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 29, 2024 to May 3, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
06/05/2024
JOY GROUP Ranks 70th in the WWD Beauty Inc Top 100, Moving Up the Ranking by 16…
As a respected publication known as the "Bible of Fashion", WWD holds considerable influence within the fashion world. The Top 100 Beauty Companies List, an annual ranking by WWD Beauty Inc of the world's largest beauty companies by sales, is a highly respected authority on the global beauty sector. As a respected publication known as the "Bible of Fashion", WWD holds considerable influence within the fashion world. The Top 100 Beauty Companies List, an annual ranking by WWD…
PR Newswire
06/05/2024
Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research…
The 50,000-square-foot facility, expected to be completed in 2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias' North American hub for large molecule analytical services. It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities. From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies…
PR Newswire
06/05/2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop…
"Seralutinib is a potential paradigm shifting therapy in PAH and PH-ILD, and we could not be more excited to partner with Gossamer to develop and bring this therapy to patients world-wide," said Giuseppe Accogli, CEO of Chiesi Group. "Gossamer shares Chiesi's commitment in using innovation to promote the health and well-being of people around the world and we are proud to add this collaboration as a key pillar to our next phase of growth." " Seralutinib is a potential…
PR Newswire
06/05/2024
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials ofAmpligen®(rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized...
Nasdaq GlobeNewswire
06/05/2024
INHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC…
The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition, inHEART received funds from a successful crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation. The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In...
PR Newswire
06/05/2024
Altri Comunicati